Maternal-child health has many medical challenges, such as pre-term birth, that are neither clearly understood nor amenable to straightforward diagnosis with conventional methods. ProteoGenix has applied innovative clinical genomic and proteomic technologies to the focused mission of developing and marketing diagnostic tests during a woman’s pregnancy. No other enterprises have brought these powerful molecular tools to this market sector.
04/07 "ProteoGenix Publishes Four Landmark Articles on Diagnostic Applications for Pregnancy" >>Read News Release
02/07 "ProteoGenix Receives Best Clinical Study Award at SMFM Annual Meeting for Preterm Birth and Intra-amniotic Infection" >>Read News Release
01/07 "ProteoGenix Publishes Identification of Novel Biomarkers in Cervical-Vaginal Fluid for Noninvasive Detection of Intra-amniotic Infection" >>Read News Release
07/04 "ProteoGenix Publishes Landmark Article on Detection of Intra-amniotic Infection in Pregnant Women" >>Read News Release
11/03 11/04 "ProteoGenix Receives Second NIH SBIR Award for "Novel Markers
for Neonatal Sepsis" >>Read News Release
Maternal-child health has many medical challenges, such as pre-term birth, that are neither clearly understood nor amenable to straightforward diagnosis with conventional methods. ProteoGenix has applied innovative clinical genomic and proteomic technologies to the focused mission of developing and marketing diagnostic tests during a woman’s pregnancy. No other enterprises have brought these powerful molecular tools to this market sector.